244 results about "Animal study" patented technology

A heart valve sewing prosthesis including an intrinsically conductive polymer. The invention includes annuloplasty rings and bands, and sewing rings or cuffs for prosthetic heart valves. Some annuloplasty rings and sewing rings include fabric that is coated with an intrinsically conductive polymer. The coating can be formed over individual filaments or fibers, or on the fabric surface as a surface layer. One intrinsically conductive polymer is polypyrrole. The intrinsically conductive polymer can be doped to facilitate the intrinsic conductivity. Some devices have a polypyrrole surface layer doped with dialkyl-napthalene sulfonate. The intrinsically conductive polymer can be deposited on a fabric using in-situ polymerization of monomeric or oligomeric species, together with a dopant. Animal studies using implanted annuloplasty rings having an intrinsically conductive polymer coating have demonstrated a substantial reduction in pannus formation and inflammatory response.

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

A magnetic field device and method for inhibiting angiogenesis and retarding growth rates of cancerous tumors present in mammals. The apparatus includes a frame, and a wire consisting of electrically conducting material. The wire is wrapped around the frame to form a coil. A source of AC current is connected to a transformer to vary the AC voltage. The AC current is passed through a bridge rectifier and then to the coil of wire enabling a DC rectified wave magnetic field to be produced therefrom. The method employs the use of an apparatus which is capable of producing a magnetic field of a particular nature which has been proven in animal studies to affect angiogenesis and retard the growth rate of cancerous tumors.

Medical devices and techniques derive breath rate, breath distention, and pulse distention measurements of a subject from a pulse oximeter system coupled to a subject. These parameters, together with the conventional physiologic parameters obtained from a pulse oximeter system, can be used to assist in controlling the ventilation levels and the anesthesia levels of the subject. The development has human applications and particular applications for animal research.

A heart valve sewing prosthesis including an intrinsically conductive polymer. The invention includes annuloplasty rings and bands, and sewing rings or cuffs for prosthetic heart valves. Some annuloplasty rings and sewing rings include fabric that is coated with an intrinsically conductive polymer. The coating can be formed over individual filaments or fibers, or on the fabric surface as a surface layer. One intrinsically conductive polymer is polypyrrole. The intrinsically conductive polymer can be doped to facilitate the intrinsic conductivity. Some devices have a polypyrrole surface layer doped with dialkyl-napthalene sulfonate. The intrinsically conductive polymer can be deposited on a fabric using in-situ polymerization of monomeric or oligomeric species, together with a dopant. Animal studies using implanted annuloplasty rings having an intrinsically conductive polymer coating have demonstrated a substantial reduction in pannus formation and inflammatory response.

The invention discloses a SgRNA (single chain guide ribonucleic acid) of the exon 2 of a specific targeted ApoE gene. The nucleotide sequence of the SgRNA is GCTTCTGGGATTACCTGCGC. The invention also discloses an ApoE-CRISPR / Cas9 carrier containing the SgRNA and application of the ApoE-CRISPR / Cas9 carrier to structuring ApoE gene knockout mammal models and to preparing ApoE gene knockout kits. TheApoE-CRISPR / Cas9 carrier structures the ApoE gene knockout mammal models; ApoE gene knockout can affect in vivo lipid metabolism of mammals and accelerate the pathogenic processes of lipid metabolismcorrelated diseases such as atherosclerosis to further accelerate the modeling process of corresponding mammal disease models and provide animal experiment basis for research on diseases such as atherosclerosis.

The invention provides for a wireless and data logging capable bio sensor system worn by individuals that transmits and stores biometric information gathered from multiple and diverse sensors on or near the individual's body. Through these sensors and its transmitters this device can convey and store vast amounts of information pertaining to an individual's physical condition and neurological state as well as the effects of physical activity on the individual's body. This data collection and sensory system could also be applied to biomechanical animal studies. Versions of this invention applied to the medical industry will allow medical specialists and patients to monitor health conditions in real time. This system will log historical biometric data to create an accurate mosaic of physical performances and conditions over a period of time. Logging of individual biometric data will create a unique and key biometric signature for each user.

The invention discloses a multi-function animal weight-losing running table and a control system thereof. The running table comprises a running machine, a weight-losing support device and a recovery robot. Running training or combination training of running training and electric stimulus is performed on the experimental animal by arranging organic glass and a stimulating electrode on the running machine; and the weight-losing running table training combining running table training and weight-losing support is performed on the experimental animal by arranging the weight-losing support device on the running machine. In the process of weight-losing running table training, the recovery robot can assist hind legs of the experimental animal in doing exercise training, so that a correct or preset training task is provided for a passive training model, the movement locus of the hind legs in the positive training model is recorded and the record is used for quantitatively evaluating the exercising function. The invention also provides a medicinal animal experiment device which is mainly used for walking function recovery of the experimental animal with hurt spinal cord and providing the animal running table training needed by sports medicine.

The invention provides a controllable microenvironment flowing gas animal experiment cabin which comprises a closed experiment cabin body, wherein an experimental animal and a temperature, humidity, pressure and oxygen concentration sensor group are placed and arranged on an air-permeable platform positioned in the closed experiment cabin body; the upper part of the cabin body is connected with a nitrogen gas source, an oxygen gas source and a compressed air source and controls gas proportion through a control valve; the compressed air source is provided with a temperature-reducing dehumidifier and an air supply filter; the experiment cabin body is provided with a humidifier and a heater; a gas inside the experiment cabin body is discharged through a flow regulating valve and a negative-pressure exhaust fan; a computer simulates different environments, such as a high-temperature environment, a low-temperature environment, a high-pressure environment, a low-pressure environment, a oxygen-rich environment, a low-oxygen environment, and the like by controlling inlet gas flows, gas concentration proportion and the parameters, such as temperature, humidity, oxygen concentration and the like, of an environment inside the experiment cabin body through a data line according to a preprogram to carry out a flowing gas animal experiment; and the parameters, such as an experiment process, a detection result, and the like, are stored or printed into a laboratory report. The controllable microenvironment flowing gas animal experiment cabin provided by the invention is widely applied to the scientific research fields of environment, medicine, military, avigation, and the like.

Medical devices and techniques derive breath rate, breath distention, and pulse distention measurements of a subject from a pulse oximeter system coupled to the subject. These parameters together with the conventional physiologic parameters obtained from a pulse oximeter system can be used to assist in controlling the ventilation levels and the anesthesia levels of the subject. The development has human applications and particular applications for animal research.

Disclosed is a method for detecting CYP450 enzymatic activity by means of micro-liver tissue incubation in vitro, which is characterized in that: a liver trace puncturing method used in clinic takes micro-liver tissues of 0.1 to 0.2g, or kills a mouse to take out the liver in an animal experiment, and builds a micro-liver tissue in vitro incubation system, then uses a one-probe medicine to perform the liquid phase chromatography tandem mass spectrometry for detecting probe substrates and concentration of corresponding metabolites, and obtains the activity of P450 enzyme according to metabolite ratios thereof. The method has the advantages of: 1. micro scale: only micro-liver tissues of 0.1 to 0.2g are needed for detecting cytochrome P450enzyme activity, and can be used for animal experiment and checking clinic micro-liver tissue liver drug enzyme activity; 2. time saving and convenience: costly ultracentrifugation equipment used in the conventional method is saved, costs and time for detection are greatly saved, and liver enzyme metabolic condition simulation is better; and 3. establishing indexes for evaluating the enzyme metabolic activity: metabolite ratios.

The present invention is generally related to the discovery of the use of a novel composition (Ri-Active™), containing a concentrate of the bioactives, micronutrients and antioxidants present in the unsaponifiable fraction of rice bran oil or rice germ oil, in the prevention and treatment of health disorders. The novel use of the by-products of rice bran oil or rice germ (and other vegetable oils) industries directly after purification and stabilization for therapeutic purposes is a unique and innovative approach that has been proved in the pilot study conducted by the current inventors. The current inventors have pioneered a new approach to prevent and treat health disorders such as cardiovascular diseases, hypercholesterolemia and diabetes which is both effective and inexpensive. The proprietary technology developed by the current inventors to produce Ri-Active™ from rice bran oil by-products or rice germ is very different from others who use these by-products to either isolate or purify individual micronutrients of value for use in other nutraceutical formulations. Most of the by-products of the edible oil refining industry are either discarded or sold at a throw away cost to the soap industry for their free fatty acid content. The novel technology and approach developed by the current inventors to utilize these low cost by-products from the edible oil refining industry and produce a highly effective therapeutic product has yielded a new and valuable use for these materials. This invention extends to the uses (therapeutic usefulness) and cost effectivity of similar whole extract concentrates of unsaponifiable micronutrients prepared from other vegetable oils rich in unsaponifiable fractions. The current discovery specifically covers the uses of Ri-Active™ (derived either from rice bran oil or rice germ oil), in preventing or treating cardiovascular disease, diabetes, hyperlipidemia, hypercholesterolemia and arteriosclerosis. Ri-Active™ contains many unsaponifiable bioactives and antioxidants of rice bran and rice germ in very high concentrations in a natural lipid matrix. These constituents in their natural lipid matrix act synergistically in the treatment of cardiovascular disease and other disorders and therefore the whole extract concentrate containing these constituents is far more efficacious than administering a mixture of procured ingredients in similar concentrations. The efficacy of this novel composition (Ri-Active™) in the treatment of cardiovascular disease risk factors has been proved in the pilot animal study conducted by the current inventors. Ri-Active™ has been tested to be safe, and highly effective in small doses.

The invention discloses the drug compound with BP neural net model. The method comprises the following steps: building non-linear mapping model of dosage and drug-effect with BP neural net; defining BP neural net model parameters; building BP neural net model non-linear mapping model. The method completely and fully utilizes the laboratory data, and uses computer to replace a great amount of animal experiment works. According to the BP neural net model, the method forecasts matching relation.

A method and system of supplying rodents, such as mice, to medical researchers pre-installs and / or embeds physiologic sensors onto or within the rodents prior to selling the modified rodents to the researchers. The specialty skills, such as small animal surgical and anesthesia skills and sensor placement and testing, are centralized in one organization rather than being spread about a collection of researchers. The subjects with preinstalled, pre-tested hardware, are sold to the researcher as needed. Communication hardware and software will be supplied for the user to convert their desktop computer into a wireless monitoring station. Additionally an external pulse oximeter for small rodents, such as mice, provides measurements on a hand or foot of the rodent with a sensor configured to avoid shunting around the rodent appendage, and configured for high heart rates (200-900 beats per minutes) of the subjects.

This invention is directed to a system and method for delivering gases, such as air, oxygen, carbon dioxide, carbon monoxide, and cigarette smoke, to a laboratory animal storage container. The system and method of the present invention allow for tight control and monitoring over the immediate environment of the animal, and allow the environment to be varied rapidly during a study. The invention is particularly useful for sleep apnea studies, but has broad application to animal studies in general.

Described herein are compositions and methods related to use of cardiosphere-derived cells and their extracellular vesicles, such as exosomes and microvesicles, for achieving anti-aging and rejuvenation. This includes discoveries for effects on heart structure, function, gene expression, and systemic parameters. For animal studies, intra-cardiac injections of neonatal rat CDCs was compared to in old and young rats including evaluation of blood, echocardiographic, haemodynamic and treadmill stress tests. For in vitro studies, human heart progenitors from older donors, or cardiomyocytes from aged rats were exposed to human CDCs or cardiosphere derived cell (CDC) derived exosomes (CDC-XO) from pediatric donors. CDCs and CDC-XOs were capable of effectuating youthful patterns of gene expression in the hearts of old, along with a variant of physiological and function benefits, including elongation of telomere length. Together, these results indicate capacity of CDCs and CDC-XO to ward off the effects of aging through rejuvenation.

The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with the prodrug 5-FC and ionizing radiation against human glioma. The present study demonstrates that infection with the viral vector expressing the mutant cytosine deaminase gene resulted in increased 5-FC-mediated cell killing, compared with vectors expressing the wild-type gene. Furthermore, a significant increase in cytotoxicity following infection with viral vector expressing the mutant cytosine deaminase gene and radiation treatment of glioma cells in vitro was demonstrated as compared to infection with viral vector expressing the wild-type gene. Animal studies showed significant inhibition of subcutaneous or intracranial tumor growth of D54MG glioma xenografts by the combination of AdbCD-D314A / 5-FC with ionizing radiation as compared with either agent alone, and with AdbCDwt / 5-FC plus radiation. These data indicate that combined treatment with this mutant enzyme / prodrug therapy and radiotherapy provides a promising approach for cancer therapy.

The invention discloses an in vitro simulated skin model. According to an establishment method of the in vitro simulated skin model, a cell culture chamber and well plates are taken as the skeleton of the in vitro simulated skin model; the cell culture chamber is inoculated with immortalized epidermis cells, and a lower chamber well plate is inoculated with fibroblast for co-culture. The establishment method is capable of simulating the basic structure of human skin effectively; the in vitro simulated skin model can be applied in evaluation of transdermal absorption and functions in promoting fibroblast proliferation and migration of cosmetics and medicinal compounds effectively, can be used for replacing conventional animal experiments and in vitro skin tissue experiments, is capable of reducing experiment cost effectively, increasing experimental flux and efficiency, and preferably satisfying requirements on scientific research ethics with more and more attention.

The invention relates to a 1 A1S-1969 recombinant protein and a preparation method and application thereof. The recombinant protein comprises 46th to 414th site amino acid sequence of 1 A1S-1969, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO. 5. The recombinant protein is high in expression amount, easy to separate and purify, efficient and safe, can be directly used with an adjuvant, and is used for the preparation of an acinetobacter baumannii infection resistant subunit vaccine and a related detection kit. Confirmed by animal experiments, the genetic engineering recombinant subunit vaccine has good acinetobacter baumannii infection resistant immune protection effect, lays a foundation for the further study on combined vaccines and multicomponent fusion vaccines, and plays an important role for development and application of prevention and control vaccines and diagnostic kits.

The patent application relates to a kind of osteoporosis treating medicine and its preparation process as well as its new use in treating fracture, osteoarthritis, osteonecrosis and climacteric syndrome. The medicine is prepared with epimedium, teasel root, red sage, anemarrhena rhizome, malaytea scurfpea fruit and rehmannia root. Clinical and animal experiment research shows that the medicine has higher curative effect and no side effect compared with other medicine for treating osteoporosis, and may be taken regularly.

The invention adopts a virtual medicine screening technology and a high-throughput screening technology, assesses the AChE inhibitory activity of more than ten thousand samples in a compound sample library and finds a batch of compounds with higher inhibitory activity by establishing a virtual acetylcholinesterase inhibitor screening method and an AChE activity detection method. Then according to the pathological features of senile dementia, the compounds with higher AChE inhibitory activity are subject to butyryl choline esterase inhibitory activity detection. Research results show that bimolecular 3-piperidyl-ethyl phenyl ketone not only has comparatively high AChE inhibitory activity, but also has very strong BuChE inhibitory activity; the results of animal experiments prove that the bimolecular 3-piperidyl-ethyl phenyl ketone can remarkably improve aphronesia caused by scopolamine and sodium nitrite and can enhance the ability of learning and memory.

The invention belongs to the technical field of genetic engineering, and particularly relates to a porcine interferon family gene and application thereof in a blue-ear porcine disease resistant medicament and a vaccine adjuvant. The porcine interferon gene is taken from a home pig genome and has anti-virus effect, and the amino acid sequence of the porcine interferon gene is SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7 or SEQ ID No. 9; and the medicament and the vaccine adjuvant are a recombinant plasmid obtained by cloning the home pig interferon gene to an eukaryotic expression vector through molecular biology technology and a live bacterial vaccine obtained by transferring the plasmid to a low virulent strain of Salmonella choleraesuls. Animal experiments prove that the medicament and the adjuvant have good safety and remarkable effect. After a home pig is directly injected, the toxicity is removed on the same day, and the protective rate can reach 80 percent. When the adjuvant is used with a blue-ear disease inactivated vaccine and after the home pig is subjected one-time immune injection, the toxicity is removed in 28 days, and the protective rate can reach 80 percent.

The invention particularly relates to a week-acting transdermal pramipexole patch and a preparation method thereof, and belongs to the field of pharmaceutic preparations. The week-acting transdermal pramipexole patch comprises a medicament storage bin, an anti-adhesion layer and a back lining layer. A double-layer patch is prepared by mixing a hydrophilic matrix with a penetration enhancer and adopting a laminated pouring method, so that the problems in multi-layer film preparation are effectively solved; furthermore, constant-speed release of a medicament within seven days can be guaranteed. An animal experiment shows that the week-acting transdermal pramipexole patch is non-irritative and non-allergenic to the skin. The patch disclosed by the invention has the advantages of definite treating effect, stable quality, high safety and convenience in use and is used for treating parkinsoncs disease.

The invention discloses a behavior experiment system to observe animal studying ability objectively, which consists of T-shaped non-transparent tank and safe table in the tank, wherein the tank is composed of transverse arm and vertical arm; the bottom of transverse arm possesses vent pipe, which connects draining hose to outlet; the height of safe table can be adjusted, which is set on one side bottom of transverse arm; two signal lamps are set on each sides of two ends of T-shaped tank transverse arms; the infrared sensor is set at intersecting part of vertical arm and transverse arm of tank; the infrared sensor, signal lamp and signal control switch constitute signal lamp controlling system through safe pressure controlling circuit.

A method for facilitating the delivery of water to a plurality of cage level barrier-type cages, for housing animals for an animal study, the method including; providing a plurality of cage level barrier-type cages for an animal study at a laboratory facility site, and disposing a bag forming apparatus at a clean side of a laboratory washroom at the laboratory facility site, wherein the bag forming apparatus is capable of providing sealed bags of water for use in the cage level barrier-type cages. The method can further include providing bag material to the laboratory facility site.

The invention provides a novel strain of cadmium-removing Lactobacillus plantarum bacterium, CCFM8610, which has a good tolerance to acidic environments. Lactobacillus plantarum CCFM8610 has a good tolerance to cadmium-containing medium and can effectively bind cadmium in vitro. Animal studies have shown that it can effectively reduce tissue cadmium accumulation and facilitate fecal cadmium excretion. Lactobacillus plantarum CCFM8610 has a great potential to be used as an active ingredient in cadmium-removing pharmaceutical drugs and fermented foods.

The invention discloses agrocybe aegerita lectin AAL-2 and a coding gene thereof, a preparation method and an application thereof. The lectin protein AAL-2 is separated and obtained from the total protein of agrocybe aegerita via affinity chromatography. The amino acid sequence is shown as SEQIDNO: 2; and the nucleotide sequence coding the protein is shown as SEQIDNO: 1. Cell tests show that the separated agrocybe aegerita lectin AAL-2 has excellent activity for killing tumor cells, can induce liver cancer cells to generate significant apoptosis. Animal experiments show that AAL-2 has relatively good therapeutic effect for tumors. Test results of sugar chip technology show that AAL-2 preferentially combines sugar or glycoprotein with the terminal of N-acetyl glucosamine, can be used as a reagent for detecting diseases in relevant with the N-acetyl glucosamine or as a reagent for detecting relevant structures of N-acetyl glucosamine.

The invention relates to a method for analyzing the stable isotope ratio of CO2 based on chromatography-mass spectrometry. The method comprises the following steps: firstly, building a mathematical model for the stable isotope ratio of CO2; secondly, purifying the carrier gas with purity lower than 10 <-5> percent with a purifier, so that the purity of the purified carrier gas is lower than 10 <-6> percent or 10 <-7> percent; thirdly, introducing the purified carrier gas in a gas chromatograph and a chromatographic column where a to-be-tested sample is placed, and then measuring the CO2 in the to-be-tested sample through a mass detector after adsorption and desorption, so as to obtain the mass number (44, 45, 46, 47, 48 and 49) of CO2 in the to-be-tested gas; and fourthly, performing substitution of the mass number (44, 45, 46, 47, 48 and 49) of CO2 in the to-be-tested gas in Table 2 to obtain 15 isotope ratios of CO2. The method achieves the purpose of subtly expressing the CO2 source by building the mathematical model, and can be applied to non-invasive detection in human health, human body medicine and planet and animal studies.

The invention discloses an application of FGF21 in preparation of a medicine for treating colorectal cancer, and belongs to the technical field of medicines. The FGF21 protein provided by the invention is a secretory protein composed of about 210 amino acids. The invention finds for the first time that the FGF21 has the effect of treating colorectal tumor, and cytological experiments and animal experiments prove that the FGF21 can inhibit proliferation, invasion and migration of a colorectal tumor cell line, and can obviously reduce the size of a tumor focus in a mouse model. The medicine which is used for treating colorectal cancer and is prepared by taking the FGF21 as an active substance has the effects of being good in safety, long in medicine effect lasting time, capable of protectingorgans from being damaged and capable of improving lipid metabolism disorder.